
Aeglea BioTherapeutics AGLE
Aeglea BioTherapeutics EV/EBITDA | AGLE
EV/EBITDA Jährlich Aeglea BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.111 | -3.48 | 0.136 | 0.152 | -0.364 | -4.37 | -3.1 | -3.65 | -3.32 | 0.39 | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 0.39 | -4.37 | -1.75 |
EV/EBITDA anderer Aktien in der Pharmaeinzelhändler
| Name | EV/EBITDA | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Cue Biopharma
CUE
|
-0.704 | $ 4.2 | -6.67 % | $ 398 M | ||
|
C4 Therapeutics
CCCC
|
-2.31 | $ 2.49 | 1.84 % | $ 206 M | ||
|
Codexis
CDXS
|
-4.31 | $ 1.0 | -5.17 % | $ 87.1 M | ||
|
Kamada Ltd.
KMDA
|
15.8 | $ 7.75 | -1.02 % | $ 447 M | ||
|
Compugen Ltd.
CGEN
|
3.32 | $ 1.83 | -2.66 % | $ 171 M | ||
|
Coherus BioSciences
CHRS
|
-1.86 | $ 0.37 | -4.06 % | $ 43.3 M | ||
|
Armata Pharmaceuticals
ARMP
|
-17.1 | $ 3.06 | 2.68 % | $ 111 M | ||
|
Celldex Therapeutics
CLDX
|
-7.28 | $ 27.36 | -2.15 % | $ 1.82 B | ||
|
Cellectis S.A.
CLLS
|
-15.8 | $ 0.9 | -9.7 % | $ 90.3 M | ||
|
Lineage Cell Therapeutics
LCTX
|
-12.5 | $ 0.78 | -4.87 % | $ 179 M | ||
|
Edesa Biotech
EDSA
|
-0.0637 | $ 2.01 | -7.59 % | $ 11.4 M | ||
|
Eli Lilly and Company
LLY
|
467 | $ 1 345.4 | -0.44 % | $ 1.21 T | ||
|
Collegium Pharmaceutical
COLL
|
38.8 | $ 24.73 | -1.9 % | $ 783 M | ||
|
Evogene Ltd.
EVGN
|
-0.106 | $ 0.32 | 1.02 % | $ 2.52 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
-1.4 | $ 2.05 | -15.81 % | $ 27.3 M | ||
|
Forte Biosciences
FBRX
|
-3.97 | $ 76.99 | 0.03 % | $ 997 M | ||
|
Curis
CRIS
|
-3.41 | $ 0.44 | -6.31 % | $ 5.79 M | ||
|
CorMedix
CRMD
|
1.83 | $ 5.25 | 4.23 % | $ 378 K | ||
|
Larimar Therapeutics
LRMR
|
-2.05 | $ 3.07 | -4.66 % | $ 255 M | ||
|
Champions Oncology
CSBR
|
392 | $ 4.34 | -1.36 % | $ 60 M | ||
|
Mesoblast Limited
MESO
|
-19.7 | $ 10.9 | -2.5 % | $ 13.2 B | ||
|
Mirum Pharmaceuticals
MIRM
|
2.69 K | $ 96.15 | 0.67 % | $ 4.83 B | ||
|
MannKind Corporation
MNKD
|
34.4 | $ 3.85 | -2.66 % | $ 1.18 B | ||
|
Dyadic International
DYAI
|
-4.95 | $ 0.29 | -6.53 % | $ 10.5 M | ||
|
Merck & Co.
MRK
|
97.3 | $ 133.34 | 0.4 % | $ 334 B | ||
|
Moderna
MRNA
|
-7.16 | $ 195.25 | -2.05 % | $ 76 B | ||
|
NuCana plc
NCNA
|
-4.24 K | $ 0.75 | 4.39 % | $ 8.42 B | ||
|
Novartis AG
NVS
|
20.9 | $ 150.51 | -0.47 % | $ 292 B | ||
|
Puma Biotechnology
PBYI
|
9.01 | $ 7.05 | -1.05 % | $ 353 M | ||
|
Fulcrum Therapeutics
FULC
|
-15.6 | $ 3.69 | -0.67 % | $ 281 M | ||
|
PDS Biotechnology Corporation
PDSB
|
-0.621 | $ 0.79 | -2.58 % | $ 36.6 M | ||
|
Geron Corporation
GERN
|
-19.5 | $ 0.87 | -4.76 % | $ 580 M | ||
|
Pharming Group N.V.
PHAR
|
118 | $ 11.54 | -5.18 % | $ 7.95 B | ||
|
Phathom Pharmaceuticals
PHAT
|
-9.75 | $ 4.65 | -8.46 % | $ 339 M | ||
|
Genmab A/S
GMAB
|
2.7 | $ 50.36 | -1.93 % | $ 3.26 B | ||
|
Gossamer Bio
GOSS
|
-2.14 | $ 10.69 | -4.81 % | $ 2.44 B | ||
|
Grifols, S.A.
GRFS
|
13.7 | $ 8.14 | -0.73 % | $ 5.53 B | ||
|
Liquidia Corporation
LQDA
|
-61 | $ 54.39 | -3.96 % | $ 4.68 B | ||
|
GlaxoSmithKline plc
GSK
|
32.5 | $ 47.8 | -0.05 % | $ 194 B | ||
|
MediciNova
MNOV
|
-3.2 | $ 1.3 | 2.36 % | $ 63.8 M | ||
|
PTC Therapeutics
PTCT
|
8.48 | $ 56.23 | -3.59 % | $ 4.47 B | ||
|
Pulmatrix
PULM
|
-3.93 K | $ 1.24 | -12.34 % | $ 4.53 B | ||
|
InflaRx N.V.
IFRX
|
-1.93 | $ 1.05 | -3.67 % | $ 70.7 M | ||
|
Immunome
IMNM
|
-5.79 | $ 15.69 | -5.54 % | $ 1.37 B | ||
|
Immuron Limited
IMRN
|
-43.1 | $ 0.9 | 5.87 % | $ 208 M | ||
|
Incyte Corporation
INCY
|
11.3 | $ 114.5 | -1.19 % | $ 22.4 B | ||
|
INmune Bio
INMB
|
-0.26 | $ 0.82 | -8.41 % | $ 20.3 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
2.14 | $ 14.88 | 0.24 % | $ 12.4 B | ||
|
Regeneron Pharmaceuticals
REGN
|
21.2 | $ 920.38 | -0.22 % | $ 96.3 B | ||
|
Ionis Pharmaceuticals
IONS
|
-76.2 | $ 26.58 | -2.37 % | $ 4.25 B |